Simcere Pharmaceutical Group Limited (Simcere Pharma, 02096) has appointed Dr. Zhou Yunshu as Chief Executive Officer effective 25 March 2026, according to a board announcement released in Hong Kong. Dr. Zhou succeeds Mr. Ren Jinsheng, who will relinquish the CEO position on the same date to focus on his duties as Chairman and executive director.
Dr. Zhou, aged 54, brings more than 30 years of research-and-commercialisation experience in China’s pharmaceutical sector. His career includes a 26-year tenure at Jiangsu Hengrui Pharmaceuticals, where he advanced from development and foreign-trade roles to vice general manager, general manager and ultimately chairman. Between August 2022 and October 2025 he was a full-time consultant at Innovent Biologics (Suzhou) Co., providing guidance on market strategy and commercialisation.
The Board acknowledged that Dr. Zhou received an administrative penalty from the China Securities Regulatory Commission on 19 September 2022 for insider dealing involving trades in Zhejiang Starry Pharmaceutical shares during April–May 2020. Penalties comprised confiscation of RMB0.45 million in gains and a RMB0.50 million fine. The Board, after legal consultation and a review by the nomination committee, determined the incident to be isolated and confirmed that Dr. Zhou faces no disqualification or market ban in either mainland China or Hong Kong.
To reinforce compliance, Simcere Pharma will: • Amend its securities-dealing policy to tighten oversight of director and senior management transactions; and • Conduct regular insider-dealing training and maintain an insiders’ register.
Dr. Zhou will receive annual remuneration of HKD 6.00 million plus a discretionary bonus, subject to Board and remuneration-committee review.
Outgoing CEO Mr. Ren has no disagreements with the Board regarding his transition and remains at the helm as Chairman. The company advises shareholders and potential investors to exercise caution when trading its shares.
Comments